Table 6 Clinical data of included studies for the efficacy of SVR on all-cause and liver-specific mortality in patients with CHC
Study | Nationality | Age | Duration of follow up | Study format | Genotype | NOS | Treatment | Death/Total SVR | Death/No SVR | Histology |
|---|---|---|---|---|---|---|---|---|---|---|
Yosida H et al. (2002) [47] | Japan | Tx: 49.5, control: 54.6 (mean) | mean 5.4 years | R | unknown | 8 | IFN-α or IFN-β | a7/817 | a49/1613 | F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVR |
Okanoue T et al. (2002) [53] | Japan | Tx: 50.4, control: 58.1 (mean) | Mean 5.6 years | R | unknown | 7 | IFN-α or lymphoblastoid | 2/426 a0/426 | 47/994 a34/994 | F3,4: 20.9% in SVR, 34.4% in control |
Imazeki F et al. (2003) [48] | Japan | Tx: 49.2, control: 53.1 (mean) | mean 8.2 years | R | 73.9% type 1 | 8 | IFN-α or IFN-β | 4/116 a1/116 | 29/239 a18/239 | F3,4: 26.7% in Tx, 29.8% in control |
Coverdale SA et al. (2004) [36] | Australia | Tx: 37, control: 38 (median) | median 9 years | P | 39.6% type 1 | 7 | IFN-α | a1/50 | a35/334 | Scheuer fibrosis score 2 |
Kasahara A et al. (2004) [17] | Japan | Tx: 53, control: 54 (median) | mean 6Â years | R | unknown | 8 | IFN | 7/738 a1/738 | 94/1930 a68/1930 | F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVR |
Shiratori Y et al. (2005) [38] | Japan | Tx: 57, control: 61 (median) | median 6.8 years | P | 71.9% type 1b | 8 | IFN-α or lymphoblastoid | 1/64 a0/64 | 44/207 a32/207 | unknown |
Yu ML et al. (2006) [39] | Taiwan | Tx: 46.9, control: 43.6 (mean) | mean 5.18–5.15 years | R | 46.2% type 1 | 8 | IFN-α with or without RBV | 4/715 a3/715 | 12/342 a11/342 | LC 15.6% in Tx, 12.1% in control |
Arase Y et al. (2007) [75] | Japan | SVR: 63, no SVR: 64 (mean) | mean 7.4 years | R | 60.4% type 1b | 8 | IFN-α/β with or without RBV | 9/140 a2/140 | 44/360 a32/360 | F3,4: 14.5 in SVR, 27.5 in no SVR |
Bruno S et al. (2007) [56] | Italy | 54.7 (mean) | Mean 96.1 months | R | 71.8% type 1 | 8 | IFN-α | 6/124 a2/120 | 114/759 a83/728 | Child A LC |
Veldt BJ et al. (2007) [58] | Europe and Canada | 48 (median) | median 2.1 years | R | 59% type 1 | 8 | IFN/PegIFN with or without RBV | 2/142 a1/142 | 24/337 a19/337 | Ishak 4–6 |
Cardoso AC et al. (2010) [63] | France | 55 (mean) | median 3.5Â years | R | 60% type 1 | 7 | IFN/PegIFN with or without RBV | a3/103 | a18/204 | F3,4: 100% |
Morgan TR et al. (2010) [64] | US | 48.6–49.6 (mean) | median 79–96 months | P | 87.2% type 1 | 8 | PegIFN with or without RBV | a1/140 | a23/386 | F3,4: 100% |
Innes HA et al. (2011) [76] | UK | 41.8 (mean) | mean 5.3Â years | R | 35.6% type 1 | 8 | IFN/PegIFN with or without RBV | 13/560 a5/560 | 75/655 a50/655 | 85.8% no LC |
Di Martino V et al. (2011) [41] | France | unknown | median 59Â months | R | 57.9% type 1 | 7 | IFN with or without RBV, or PegIFN with RBV | 0/59 a0/59 | 9/125 a5/125 | 55.5%Â F2 or greater |
Velosa J et al. (2011) [65] | Portugal | 51.7 (mean) | mean 6.4Â years | R | 61% type 1 | 7 | IFN/PegIFN with or without RBV | a0/39 | a15/91 | compensated LC |
Iacobellis A et al. (2011) [66] | Italy | 59–62 (mean) | mean 51 months | P | 57.3% type 1 | 7 | PegIFN with RBV | a2/24 | a23/51 | decompensated LC |
Backus LI et al. (2011) [69] | US | 51–53 (mean) | median 3.8 years | R | 72.1% type 1 | 6 | PegIFN with RBV | 525/7434 | 1440/9430 | 13% LC |
Yamasaki K et al. (2012) [49] | Japan | 60.9 (mean) | median 11.5 years | P | 59.9% type 1b | 7 | IFN-α or β or lymphoblastoid with or without RBV | 9/72 a1/72 | 16/80 a5/80 | unknown |
van der Meer AJ et al. (2012) [71] | Europe and Canada | 48 (mean) | median 8.4 years | R | 68% type 1 | 8 | IFN/PegIFN with or without RBV | 13/125 a3/125 | 100/405 a103/405 | Ishak 4–6 |
Maruoka D et al. (2012) [43] | Japan | 50.4–54 (mean) | mean 9.9 years | R | 73.6% type 1 | 8 | IFN-α/IFN-β with or without RBV | 10/221 a2/221 | 74/356 a50/356 | F3,4: 24.3% in Tx, F4: 43.1% in control |
Cozen ML et al. (2013) [44] | US | 50.98 (mean) | mean 10 years | R | 68.7% type 1 | 8 | IFN-α with or without RBV | 6/69 | 25/90 | F3,4: 19% (30.2% in Tx, 10.1% in control) |
Alfaleh FZ et al. (2013) [72] | Saudi Arabia, Egypt | 48 (mean) | mean 63.8Â months | P | 30.6% type 4 | 8 | PegIFN with or without RBV | 0/62 a0/62 | 4/95 a8/95 | F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR) |
Aleman S et al. (2013) [45] | Sweden | 51 (mean) | mean 5.3Â years | R | 50% type 1 | 8 | PegIFN with RBV | 11/110 a4/110 | 48/193 a35/193 | LC |
Singal AG et al. (2013) [77] | US | 48 (median) | median 36–72 months | R | 68.6% type 1 | 7 | PegIFN with RBV | 2/83 | 41/159 | 17.3% LC |
Dieperink E et al. (2014) [78] | US | 51.4 (mean) | median 7.5Â years | R | 70% type 1 | 8 | IFN/PegIFN with or without RBV | 19/222 a6/222 | 81/314 a56/314 | F3,4: 54.5% (41.3% in SVR, 64.7% in no SVR) |
Kutala BK et al. (2015) [50] | France | 50 (median) | median 5.5Â years | R | 55.7% type 1 | 8 | IFN/PegIFN with or without RBV | 3/104 | 27/221 | F3,4: 100% |
Di Marco V et al. (2016) [73] | Italy | 58 (mean) | median 7.6Â years | P | 83.4% type 1 | 8 | PegIFN with RBV | a8/108 | a98/336 | compensated LC |